If you liked this article you might like

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena
Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug
Markets Very Sluggish as August Nears an End
These 7 Stocks Under $10 Could Make You a Lot of Money